Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
$18.51
+0.2%
$19.68
$10.21
$25.67
$4.42B0.433.68 million shs1.95 million shs
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
$1.20
-1.6%
$1.18
$0.72
$6.45
$12M0.22400,497 shs250,218 shs
Eiger BioPharmaceuticals, Inc. stock logo
EIGR
Eiger BioPharmaceuticals
$4.35
$1.10
$43.35
$2.55M1.83103,866 shs137,800 shs
Novavax, Inc. stock logo
NVAX
Novavax
$6.84
-3.7%
$6.80
$5.01
$17.81
$1.15B2.696.28 million shs3.96 million shs
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
$0.76
-6.9%
$0.84
$0.52
$5.17
$69.07M1.641.13 million shs229,298 shs
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
+0.22%+1.18%-15.36%-4.59%+54.25%
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
-1.64%+5.26%-3.23%+57.40%-77.21%
Eiger BioPharmaceuticals, Inc. stock logo
EIGR
Eiger BioPharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Novavax, Inc. stock logo
NVAX
Novavax
-3.66%+0.66%-3.53%+16.72%-42.71%
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
-6.88%-0.46%-7.90%+26.41%-78.85%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
3.9596 of 5 stars
3.71.00.00.03.12.53.1
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
1.4474 of 5 stars
0.02.00.04.72.70.80.6
Eiger BioPharmaceuticals, Inc. stock logo
EIGR
Eiger BioPharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Novavax, Inc. stock logo
NVAX
Novavax
4.3512 of 5 stars
3.11.00.04.71.60.83.1
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
4.2984 of 5 stars
3.15.00.04.72.81.70.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
3.33
Buy$27.6749.47% Upside
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
0.00
N/AN/AN/A
Eiger BioPharmaceuticals, Inc. stock logo
EIGR
Eiger BioPharmaceuticals
0.00
N/AN/AN/A
Novavax, Inc. stock logo
NVAX
Novavax
2.29
Hold$17.00148.54% Upside
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
2.25
Hold$6.11702.93% Upside

Current Analyst Ratings Breakdown

Latest STRO, EIGR, NVAX, BCLI, and ADMA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/17/2025
Novavax, Inc. stock logo
NVAX
Novavax
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageSell$6.00
6/16/2025
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Overweight$2.00
5/19/2025
Novavax, Inc. stock logo
NVAX
Novavax
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
5/19/2025
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderperform ➝ Underperform$1.00 ➝ $0.80
5/9/2025
Novavax, Inc. stock logo
NVAX
Novavax
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$9.00 ➝ $7.00
5/8/2025
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetStrong-Buy ➝ Strong-Buy$25.00 ➝ $32.00
4/29/2025
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$2.00 ➝ $2.00
(Data available from 7/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
$459.38M9.62$0.54 per share34.12$1.48 per share12.51
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
N/AN/AN/AN/A($1.36) per shareN/A
Eiger BioPharmaceuticals, Inc. stock logo
EIGR
Eiger BioPharmaceuticals
$15.77M0.00N/AN/A$37.68 per share0.00
Novavax, Inc. stock logo
NVAX
Novavax
$682.16M1.62N/AN/A($3.89) per share-1.76
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
$62.04M1.04N/AN/A$0.54 per share1.41
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
$197.67M$0.8521.7826.83N/A45.01%47.16%30.51%8/6/2025 (Estimated)
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
-$11.62M-$3.36N/AN/AN/AN/AN/A-519.50%8/13/2025 (Estimated)
Eiger BioPharmaceuticals, Inc. stock logo
EIGR
Eiger BioPharmaceuticals
-$96.78M-$59.16N/AN/AN/A-590.80%-332.49%-99.77%N/A
Novavax, Inc. stock logo
NVAX
Novavax
-$187.50M$2.652.5885.500.0638.14%-115.51%29.99%8/14/2025 (Estimated)
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
-$227.46M-$2.98N/AN/AN/A-373.66%-347.60%-59.46%8/12/2025 (Estimated)

Latest STRO, EIGR, NVAX, BCLI, and ADMA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
-$0.38-$0.45-$0.07-$0.45N/AN/A
5/8/2025Q1 2025
Novavax, Inc. stock logo
NVAX
Novavax
$0.71$2.93+$2.22$2.93$204.08 million$666.66 million
5/8/2025Q1 2025
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
-$0.63-$0.91-$0.28-$0.91$11.61 million$17.40 million
5/7/2025Q1 2025
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
$0.16$0.14-$0.02$0.11$116.40 million$114.80 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
N/AN/AN/AN/AN/A
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
N/AN/AN/AN/AN/A
Eiger BioPharmaceuticals, Inc. stock logo
EIGR
Eiger BioPharmaceuticals
N/AN/AN/AN/AN/A
Novavax, Inc. stock logo
NVAX
Novavax
N/AN/AN/AN/AN/A
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
0.22
6.58
3.36
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
N/A
0.21
0.21
Eiger BioPharmaceuticals, Inc. stock logo
EIGR
Eiger BioPharmaceuticals
N/A
3.31
3.24
Novavax, Inc. stock logo
NVAX
Novavax
N/A
2.06
2.03
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
N/A
2.16
2.16

Institutional Ownership

CompanyInstitutional Ownership
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
75.68%
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
14.33%
Eiger BioPharmaceuticals, Inc. stock logo
EIGR
Eiger BioPharmaceuticals
62.46%
Novavax, Inc. stock logo
NVAX
Novavax
53.04%
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
96.99%
CompanyEmployeesShares OutstandingFree FloatOptionable
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
530238.73 million230.38 millionOptionable
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
409.84 million8.74 millionOptionable
Eiger BioPharmaceuticals, Inc. stock logo
EIGR
Eiger BioPharmaceuticals
561.48 million1.42 millionOptionable
Novavax, Inc. stock logo
NVAX
Novavax
1,990161.97 million160.35 millionOptionable
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
24084.46 million81.42 millionOptionable

Recent News About These Companies

Sutro Biopharma downgraded to Neutral from Buy at H.C. Wainwright
Sutro Biopharma presents expanded data from REFRalphaME-01 trial
Wedbush Downgrades Sutro Biopharma (STRO)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
ADMA Biologics stock logo

ADMA Biologics NASDAQ:ADMA

$18.51 +0.04 (+0.22%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$18.36 -0.16 (-0.84%)
As of 07/11/2025 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Brainstorm Cell Therapeutics stock logo

Brainstorm Cell Therapeutics NASDAQ:BCLI

$1.20 -0.02 (-1.64%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$1.22 +0.02 (+1.25%)
As of 07/11/2025 06:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.

Eiger BioPharmaceuticals stock logo

Eiger BioPharmaceuticals NASDAQ:EIGR

Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.

Novavax stock logo

Novavax NASDAQ:NVAX

$6.84 -0.26 (-3.66%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$6.86 +0.02 (+0.31%)
As of 07/11/2025 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Sutro Biopharma stock logo

Sutro Biopharma NASDAQ:STRO

$0.76 -0.06 (-6.88%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$0.78 +0.02 (+2.04%)
As of 07/11/2025 05:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.